Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: A population-based study

Annals of Internal Medicine

Volumn 130, Issue 1, 1999, Pages 14-22

  Petty, George W ^a   Brown Jr , Robert D ^a   Whisnant, Jack P ^a   Sicks, JoRean D ^a   O'Fallon, W Michael ^a   Wiebers, David O ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGED; ARTICLE; BRAIN ISCHEMIA; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; TREATMENT OUTCOME;

EID: 0032910944     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-1-199901050-00004     Document Type: Article

References (43)

1. Sullivan LW. Striking out stroke in America. Be stroke smart. National Stroke Association Newsletter. 1992;9:1-3.
2. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27:373-80.
3. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998;50:208-16.
4. Sherman DG, Dyken ML Jr. Gent M, Harrison JG, Hart RG, Mohr JP. Antithrombotic therapy for cerebrovascular disorders. An update Chest. 1995;108(4 Suppl):444S-56S.
5. Major ongoing stroke trials. Stroke. 1997;28:475-9
6. Orencia AJ, Whisnant JP. Generalizability of clinical trials to the natural history of stroke. In: Whisnant JP, ed. Stroke: Populations, Cohorts, and Clinical Trials. Boston: Butterworth-Heinemann; 1993:238-45.
7. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch intern Med. 1994;154:1945-53.
8. Melton LJ 3d. History of the Rochester Epidemiology Project Mayo Clin Proc. 1996;71:266-74.
9. Kunitz SC, Gross CR, Heyman A, Kase CS, Mohr JP, Price TR, et al. The pilot Stroke Data Bank: definition, design, and data. Stroke. 1984;15:740-6.
10. Rankin J. Cerebral vascular accidents in patients over the age of 60. I. General considerations. Scott Med J. 1957;2:127-36.
11. Broderick JP, Phillips SJ, O'Fallon WM, Frye RL, Whisnant JP. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke. 1992;23:1250-6.
12. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol. 1997;92:419-24.
13. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol. 1995;90: 206-10.
14. Immediate anticoagulation of embolic stroke: a randomized trial. Cerebral Embolism Study Group. Stroke. 1983;14:668-76.
15. Putman SF, Adams HP Jr. Usefulness of heparin in initial management of patients with recent transient ischemic attacks. Arch Neurol. 1985;42:960-2.
16. Ramirez-Lassepas M, Quiñones MR, Nino HH. Treatment of acute ischemic stroke. Open trial with continuous intravenous heparinization. Arch Neurol. 1986;43:386-90.
17. Keith DS. Phillips SJ, Whisnant JP, Nishimaru K, O'Fallon WM. Heparin therapy for recent transient focal cerebral ischemia. Mayo Clin Proc. 1987; 62:1101-6.
18. Haley EC Jr, Kassell NF, Torner JC. Failure of heparin to prevent progression in progressing ischemic infarction. Stroke. 1988;19:10-4.
19. Biller J, Bruno A, Adams HP Jr, Godersky JC, Loftus CM, Mitchell VL, et al. A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study. Stroke. 1989;20:441-7.
20. Fields WS, Lemak NA. Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301-14.
21. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet. 1991;338:1345-9.
22. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med. 1991;325:1261-6.
23. Groch SN, McDevitt E, Wright IS. A long-term study of cerebral vascular disease. Ann Intern Med. 1961;55:358-67.
24. Report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease. Neurology. 1961;11(Pt 2):132-8.
25. Baker RN, Broward JA, Fang HC, Fisher CM, Groch SN, Heyman A, et al. Anticoagulant therapy in cerebral infarction. Report on cooperative study. Neurology. 1962;12:823-35.
26. Hill AB, Marshall J, Shaw DA. Cerebrovascular disease: trial of long-term anticoagulant therapy. Br Med J. 1962;2:1003-6.
27. McDowell F, McDevitt E. Treatment of the completed stroke with long-term anticoagulant: six and one-half years experience. In: Millikan CH, Siekert RG, Whisnant JP, eds Cerebral Vascular Disease. New York: Grune & Stratton; 1965;185-99.
28. Enger E, Bøyesen S. Long-term anticoagulant therapy in patients with cerebral infarction. A controlled clinical study. Acta Med Scand. 1965;178(Suppl 438):7-51.
29. Pearce JM, Gubbay SS, Walton JN. Long-term anticoagulant therapy in transient cerebral ischaemic attacks. Lancet. 1965;13:6-9.
30. Eriksson SE. Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks. Acta Neural Scand. 1985;71:485-93.
31. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med. 1995;333:5-10.
32. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology. 1995;45:1488-93.
33. Kronmal RA, Hart RG, Manolio TA, Talbert RL, Beauchamp NJ, Newman A. Aspirin use and incident stroke in the Cardiovascular Health Study. CHS Collaborative Research Group Stroke. 1998;29:887-94.
34. Levine MM, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest. 1995;108(4 Suppl):276S-90S.
35. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315-28.
36. Davenport RJ, Dennis MS, Warlow CP. Gastrointestinal hemorrhage after acute stroke. Stroke. 1996;27:421-4.
37. Pessin MS, Estol CJ, Lafranchise F, Caplan LR. Safety of anticoagulation after hemorrhagic infarction. Neurology. 1993,43:1298-303.
38. Petty GW, Lennihan L, Mohr JP, Mauser WA, Weitz J, Owen J, et al. Complications of long-term anticoagulation. Ann Neurol. 1988;23:570-4.
39. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994:120:897-902.
40. Landefeld CS, Goldman L Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989:87:144-52.
41. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995;70:725-33.
42. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993;118:511-20.
43. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med. 1996;124:970-9.